Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

TZP-101

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Introduction: Gastroparesis is an important clinical disorder characterised by delayed gastric emptying in the absence of… 
Highly Cited
2011
Highly Cited
2011
Aliment Pharmacol Ther 2011; 33: 679–688 
Highly Cited
2011
Highly Cited
2011
High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2010
Highly Cited
2010
Background  Gastroparesis, a chronic disorder of abnormal gastric motility, is common in patients with diabetes mellitus. A… 
Highly Cited
2010
Highly Cited
2010
PURPOSE: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in… 
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2009
Highly Cited
2009
Background  TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis. 
2009
2009
Ghrelin, the natural ligand of the growth hormone secretagogue receptor (ghrelin receptor), is an orexigenic gut hormone with… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
The authors evaluate the human safety, tolerability, pharmacokinetics, and pharmacodynamics of TZP‐101, an agonist of the hGHS… 
2008
2008
The peptide hormone ghrelin exerts a wide spectrum of activities including the stimulation of GH release, feeding, and… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2007
Highly Cited
2007
Postoperative ileus (POI) is a major cause of postoperative complications and prolonged hospitalization. Ghrelin, which is the… 
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3